The Food and Drug Administration has agreed to review a treatment for a rare, genetically defined form of ALS developed by Biogen, even though results from a clinical trial failed to show a definitive benefit for patients.
Biogen said Tuesday that U.S. regulators accepted its application for the drug, called tofersen, and that it will undergo a priority review with an approval decision expected by Jan. 25.
The company had not previously disclosed the FDA submission for tofersen, but waited for the agency to accept the filing before making a public announcement.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect